Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.75 |
| ▸ | HPGD | P15428 | 1/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 4/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | CRHBP | P24387 | 1/20 | 0.61 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 3/20 | 0.60 |
| ▸ | CES2 | O00748 | 1/20 | 0.60 |
| ▸ | CES1 | P23141 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8544673 | 0.86 | ALDH1A1 (0.72) | ALDH1A1HPGDSMN1; SMN2RAB9AMEN1 | |
| SCHEMBL31216547 | 0.86 | TSHR (0.68) | ALDH1A1SMN1; SMN2RAB9AMEN1KMT2A | |
| SCHEMBL11791030 | 0.86 | MEN1 (0.69) | ALDH1A1SMN1; SMN2RAB9AMEN1KMT2A | |
| SCHEMBL7539576 | 0.85 | POLB (0.81) | SMN1; SMN2RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL4322620 | 0.84 | SMN1; SMN2 (0.64) | ALDH1A1HPGDSMN1; SMN2RAB9AMEN1 | |
| SCHEMBL16515689 | 0.84 | KMT2A (0.68) | ALDH1A1SMN1; SMN2RAB9AMEN1KMT2A | |
| SCHEMBL655886 | 0.83 | HTT (0.69) | ALDH1A1SMN1; SMN2RAB9AMEN1KMT2A | |
| SCHEMBL10355 | 0.82 | KMT2A (0.69) | ALDH1A1HPGDSMN1; SMN2RAB9AMEN1 | |
| SCHEMBL11060904 | 0.82 | KMT2A (0.73) | ALDH1A1HPGDRAB9AMEN1KMT2A | |
| SCHEMBL7539578 | 0.81 | SMN1; SMN2 (1.00) | ALDH1A1HPGDSMN1; SMN2RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306067-A1 | Modulators of Chemokine Receptor Activity | WEIGAND KLAUS | 2008-12-11 | — | — | US | disclosed |
| EP-1943235-A1 | ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Novartis AG (CH) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007048771-A1 | ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | NOVARTIS AG (CH) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306067-A1 | Modulators of Chemokine Receptor Activity | CCR3, CCR1, CCR4 | ALDH1A1 906/4885HPGD 388/4885SMN1; SMN2 4305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.